Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation.

Lung transplantation with its attendant life-long immunosuppression contributes to bone loss and its sequelae, fractures and kyphosis, in patients with lung disease, many of whom already suffer from severe osteoporosis. Patients with cystic fibrosis (CF) are one of the most severely affected groups. We conducted a controlled, randomized, nonblinded trial of pamidronate (30 mg intravenously every 3 mo) with vitamin D (800 IU/d) and calcium (1 g/d) (n = 16) compared with vitamin D and calcium alone (n = 18, the control subjects) for 2 yr in 34 patients after lung transplant to improve bone mineral density (BMD).

Increased rate of fractures and severe kyphosis: sequelae of living into adulthood with cystic fibrosis.

Background: Osteoporosis occurs in patients with cystic fibrosis as they age, but its clinical implications are not well defined.

Objective: To determine the clinical effect of decreased bone mineral density in adults with cystic fibrosis and to assess possible clinical predictors of osteoporosis.

Design: Retrospective cohort study.

Correlation of kinetic energy losses in high-energy collision-induced dissociation with observed peptide product ions.

In collision-induced dissociation, some of an incident parent ion's kinetic energy is converted into internal energy upon collision with a neutral target. The kinetic energy lost is related to the amount of internal energy deposited into any individual ion. To see dissociations of different critical energies on the same time scale, different amounts of internal energy need to be deposited.